CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Early detection of myeloproliferative neoplasms in a Danish general population study

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134:469–79. http://www.ncbi.nlm.nih.gov/pubmed/31217187.

  2. 2.

    Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A. Diagnostic impact of the 2016 revised who criteria for polycythemia vera. Am J Hematol. 2017;92:417–9. http://www.ncbi.nlm.nih.gov/pubmed/28196400.

  3. 3.

    Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 2015;26:344–7. https://linkinghub.elsevier.com/retrieve/pii/S0953620515000928.

  4. 4.

    Sørensen AL, Hasselbalch HC. Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2016;41:27–35. http://www.ncbi.nlm.nih.gov/pubmed/26718091.

  5. 5.

    Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95:1216–20. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2895049&tool=pmcentrez&rendertype=abstract.

  6. 6.

    Pettersson H, Knutsen H, Holmberg E, Andréasson B. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015;94:152–6. http://www.ncbi.nlm.nih.gov/pubmed/25039361.

  7. 7.

    Fallah M, Kharazmi E, Sundquist J, Hemminki K. Higher risk of primary cancers after polycythaemia vera and vice versa. Br J Haematol. 2011;153:283–5. http://www.ncbi.nlm.nih.gov/pubmed/21275965.

  8. 8.

    Craver B, El Alaoui K, Scherber R, Fleischman A. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers. 2018;10:104. http://www.ncbi.nlm.nih.gov/pubmed/29614027.

  9. 9.

    Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?. Leuk Res. 2009;33:11–8. http://www.sciencedirect.com/science/article/pii/S0145212608002786.

  10. 10.

    Bergholdt HKM, Bathum L, Kvetny J, Rasmussen DB, Moldow B, Hoeg T, et al. Study design, participation and characteristics of the Danish General Suburban Population Study. Dan Med J. 2013;60:A4693.

  11. 11.

    Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A, et al. World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations—the Danish experience. Am J Hematol. 2013;88:1012–6. http://www.ncbi.nlm.nih.gov/pubmed/23897670.

  12. 12.

    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2017.

  13. 13.

    Ye X-P, Bao S, Gao H-M, Guo Y, Wei Y-P. A case of myeloproliferative neoplasm with a normal complete blood cell count: a novel problem of the JAK2 era. Oncol Lett. 2016;11:2134–6. https://www.spandidos-publications.com/10.3892/ol.2016.4192.

Download references

Acknowledgements

This work was supported by grants from Region Zealand Research Foundation; Manufacturer Einar Willumsens Memorial Foundation; Anders Hasselbalch’s Foundation Fighting Leukemia; Carpenter Joergen Holm and Wife Elisa F. Hansen’s Memorial Foundation; Else and Mogens Wedell-Wedellborgs Foundation; the Hoejmosegaard Scholarship; Eva and Henry Fraenkels Memorial Foundation; Dagmar Marshalls Foundation; Candys Foundation; A.V. Lykfeldt and Wife’s Scholarship; and Aase and Ejnar Danielsen’s Foundation. The Danish General Suburban Population Study was funded by the Region Zealand Research Foundation; Naestved Hospital Foundation; Naestved Municipality; Johan and Lise Boserup Foundation; TrygFonden; Johannes Fog’s Foundation; Region Zealand; Naestved Hospital; The National Board of Health; and the Local Government Denmark Foundation. The sponsors are public or nonprofit organizations that support science in general. They had no role in gathering, analysing, or interpreting the data.

Author information

Affiliations

Authors

Corresponding author

Correspondence to S. Cordua.

Ethics declarations

Conflict of interest

NP: Novartis: research support, honorarium, travel grant; InCyte: research support. LMRG: NanoString: research funding. HCH: Novartis: research grant; AOP Orphan: advisory board. SC, LK, VS, MK, and CE declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cordua, S., Kjaer, L., Skov, V. et al. Early detection of myeloproliferative neoplasms in a Danish general population study. Leukemia (2021). https://doi.org/10.1038/s41375-021-01159-8

Download citation

Search

Quick links